$RIGL New paper released on Medxriv titled: Dynamic dysregulation of IL-6 and genes functional in NETosis, complementand coagulation in severe COVID-19 illness. medrxiv.org/content/10.1101... The paper makes the case for the inhibitors of NETosis as this underlies severe disease. Keep in mind that SYK inhibition (a key action of fostamatinib) is being explored in the NIH/NHLBI-Sponsored Trial in collaboration with Inova. In other words, in my opinion, RIGL has the most advanced candidate for NETosis.